The BZW2 Knockout HT29 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the BZW2 gene has been disrupted. This heterogeneous pool of HT29 cells enables loss-of-function studies of BZW2, avoiding clonal artifacts and preserving the genetic diversity of the edited population. The polyclonal format is particularly suited for pooled screening approaches and for assessing overall pathway dependencies without confounding effects from single-cell bottleneck events. This knockout model serves as a valuable tool for investigating the role of BZW2 in translation initiation and oncogenic signaling.
The HT29 cell line, derived from a human colon adenocarcinoma, manifests an epithelial morphology and forms polarized monolayers characteristic of intestinal epithelium. These cells retain key features such as mucin production and barrier function, rendering them a physiologically relevant in vitro model for colorectal cancer and mucosal biology. The background offers a well-characterized system for studying tumor cell behavior, including proliferation, differentiation, and response to therapeutic agents within a gastrointestinal context.
BZW2 encodes a translation initiation factor that enhances protein synthesis by facilitating the assembly of the translation pre-initiation complex. It preferentially promotes the translation of oncogenic mRNAs, including cyclin D1 and c-MYC, thereby driving cell cycle progression and tumor growth. BZW2 operates downstream of major oncogenic pathways: it is transcriptionally activated by MYC and ??-catenin/TCF4 complexes and regulated by mTOR signaling through downstream effectors such as S6K and 4E-BP1. Mechanistically, BZW2 interacts with the eIF3 complex and ribosome subunits to modulate cap-dependent translation, and its activity amplifies pro-survival signals via upregulation of anti-apoptotic BCL-2 family proteins.
In the HT29 colorectal adenocarcinoma background, disruption of BZW2 is predicted to attenuate the translation of key oncogenic drivers, thereby impairing cell proliferation and tumorigenic potential. Because HT29 cells express functional APC and harbor mutant p53, they provide a distinctive genetic context in which to evaluate BZW2-dependent translational control and its cross-talk with the Wnt/??-catenin and mTOR pathways. The polyclonal knockout pool enables robust assessment of these effects while capturing population-level heterogeneity, making it an especially relevant model for colorectal cancer research and for probing mechanisms of translational dysregulation.
This knockout cell population supports a broad range of experimental applications, including oncogene functional studies, translational control mechanisms, and drug target validation. Researchers can employ assays such as Western blotting for BZW2 and downstream targets, RT-qPCR for mRNA expression, cell proliferation assays (MTT or BrdU), apoptosis assays (Annexin V), colony formation, and migration and invasion analyses. Pathway engagement can be directly measured by assessing mTOR activity via phospho-S6K levels or by using ??-catenin/TCF reporter assays. These applications facilitate dissection of BZW2??s role in cancer biology and the development of therapeutic strategies. For further technical details or to inquire about custom applications, please contact Ascent Research.
